Search Results

You are looking at 1 - 10 of 48 items for :

  • "metastatic colon cancer" x
  • Refine by Access: All x
Clear All
Full access

Metastatic Colon Cancer, Version 3.2013

Featured Updates to the NCCN Guidelines

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass

NCCN Guidelines Insights : Metastatic Colon Cancer, Version 3.2013 Version 3.2013 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express

Full access

Targeted Strategies in the Treatment of Metastatic Colon Cancer

Diane Reidy and Leonard Saltz

Advances in the understanding of tumor biology have led to the identification of important cellular processes involved in the pathogenesis of colon cancer. Drugs that interfere with these critical pathways are known as targeted agents. The goal of these therapies is to selectively interrupt the signal transduction pathways responsible for tumor growth and survival. Some of these targeted agents have made important, albeit modest, contributions to the treatment of patients with metastatic colorectal cancer. However, the activity levels with the currently available targeted therapies are far lower than experts had hoped, and toxicities are often nontrivial. This article reviews the available therapies, the data that justify their use, and the challenges of optimizing targeted therapies through combinations with cytotoxic chemotherapies and other targeted agents. Finally, some newer drugs and strategies currently being tested in clinical trials are discussed.

Full access

Challenges in the Management of Older Patients With Colon Cancer

Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger

with early-stage colon cancer. Issues in the Treatment of Metastatic Colon Cancer in Older Patients Surgical Considerations Early studies evaluating the surgical resection of liver metastases in colorectal cancer reported an increase in

Full access

Melanoma, Version 2.2013

Featured Updates to the NCCN Guidelines

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Maria Ho

: Integrate into professional practice the updates to NCCN Guidelines for Melanoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Melanoma NCCN Guidelines Insights : Metastatic Colon Cancer, Version

Full access

Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab

Emil Lou, Donna D'Souza, and Andrew C. Nelson

and S3 nerve roots. CT scan of the chest characterized a 1.1 x 1.2-cm right middle lobe nodule, consistent with potentially a primary bronchogenic carcinoma versus metastatic colon cancer. There was also a tiny 0.3-cm indeterminate nodular density in

Full access

Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction

Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa

-line treatment in advanced colorectal cancer . J Clin Oncol 2000 ; 18 : 2938 – 2947 . 10. Fakih MG . 5-Fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction . Oncology 2004

Full access

Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer

Aparna Parikh, Chloe Atreya, W. Michael Korn, and Alan P. Venook

knowledge, of successful single-agent treatment of HER2 -amplifed CRC with trastuzumab-DM1. Clinical trials targeting patients with HER2 -mutated and -amplified metastatic colon cancer are currently underway. Molecular insights from investigating HER2

Full access

Optimizing Neoadjuvant Therapy for Rectal Cancer With Oxaliplatin

Ludmila Katherine Martin and Tanios Bekaii-Saab

Neoadjuvant chemoradiation (CRT) is standard treatment for stage II-III rectal cancer. Fluoropyrimidine-based CRT prolongs disease-free survival over adjuvant CRT and improves local control over both adjuvant CRT and neoadjuvant radiotherapy alone, but does not prolong overall survival. New approaches to neoadjuvant therapy may improve outcome in this disease. Oxaliplatin, a standard component of chemotherapy for the treatment of both resected and metastatic colon cancer, is a potent radiosensitizer with synergistic radiosensitizing activity in combination with 5-FU in preclinical studies. Early clinical trials showed promising activity with the addition oxaliplatin to 5-FU-based CRT in stage II-III rectal cancer; however, early data from phase III trials seem to be disappointing. This article reviews the existing literature and explores the potential role of oxaliplatin as part of neoadjuvant CRT for rectal cancer.

Full access

JNCCN CE Offerings

: Brentuximab in the Treatment of CD30-Positive Enteropathy-Associated T-Cell Lymphoma Expiration Date: 2/18/14 NCCN Guidelines® Insights: Metastatic Colon Cancer, Version 3.2013 Expiration Date: 2/18/14 Using Multigene Tests to Select Treatment for

Full access

CLO23-047: Ivosidenib as a Novel Treatment for Patients With Isocitrate Dehydrogenase-1 Positive Advanced Colon Cancer

Krishna Desai, Kristal Pereira, Akhil Jain, Sabah Iqbal, and Rajesh Thirumaran

Background: Colorectal cancer (CRC) is a commonly diagnosed cancer. We present an intriguing case of metastatic colon cancer, with a rare mutation in Isocitrate Dehydrogenase (IDH)-1, responsive to Ivosidenib. Case Presentation: A 37-year